Literature DB >> 34544801

Elevated N-Linked Glycosylation of IgG V Regions in Myasthenia Gravis Disease Subtypes.

Caleigh Mandel-Brehm1, Miriam L Fichtner2,3, Ruoyi Jiang3, Valerie J Winton4, Sara E Vazquez1, Minh C Pham3, Kenneth B Hoehn5, Neil L Kelleher6,7, Richard J Nowak2, Steven H Kleinstein3,5,8, Michael R Wilson9, Joseph L DeRisi1,10, Kevin C O'Connor11,3.   

Abstract

Elevated N-linked glycosylation of IgG V regions (IgG-VN-Glyc) is an emerging molecular phenotype associated with autoimmune disorders. To test the broader specificity of elevated IgG-VN-Glyc, we studied patients with distinct subtypes of myasthenia gravis (MG), a B cell-mediated autoimmune disease. Our experimental design focused on examining the B cell repertoire and total IgG. It specifically included adaptive immune receptor repertoire sequencing to quantify and characterize N-linked glycosylation sites in the circulating BCR repertoire, proteomics to examine glycosylation patterns of the total circulating IgG, and an exploration of human-derived recombinant autoantibodies, which were studied with mass spectrometry and Ag binding assays to respectively confirm occupation of glycosylation sites and determine whether they alter binding. We found that the frequency of IgG-VN-Glyc motifs was increased in the total BCR repertoire of patients with MG when compared with healthy donors. The elevated frequency was attributed to both biased V gene segment usage and somatic hypermutation. IgG-VN-Glyc could be observed in the total circulating IgG in a subset of patients with MG. Autoantigen binding, by four patient-derived MG autoantigen-specific mAbs with experimentally confirmed presence of IgG-VN-Glyc, was not altered by the glycosylation. Our findings extend prior work on patterns of Ig V region N-linked glycosylation in autoimmunity to MG subtypes.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34544801      PMCID: PMC8492536          DOI: 10.4049/jimmunol.2100225

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  65 in total

1.  Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data.

Authors:  Namita T Gupta; Jason A Vander Heiden; Mohamed Uduman; Daniel Gadala-Maria; Gur Yaari; Steven H Kleinstein
Journal:  Bioinformatics       Date:  2015-06-10       Impact factor: 6.937

2.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

3.  Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region.

Authors:  Fleur S van de Bovenkamp; Ninotska I L Derksen; Pleuni Ooijevaar-de Heer; Karin A van Schie; Simone Kruithof; Magdalena A Berkowska; C Ellen van der Schoot; Hanna IJspeert; Mirjam van der Burg; Ann Gils; Lise Hafkenscheid; René E M Toes; Yoann Rombouts; Rosina Plomp; Manfred Wuhrer; S Marieke van Ham; Gestur Vidarsson; Theo Rispens
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-05       Impact factor: 11.205

4.  Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis.

Authors:  Panos Stathopoulos; Aditya Kumar; Richard J Nowak; Kevin C O'Connor
Journal:  JCI Insight       Date:  2017-09-07

5.  Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3.

Authors:  A Rødgaard; F C Nielsen; R Djurup; F Somnier; S Gammeltoft
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

Review 6.  The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes.

Authors:  Alexander Marx; Frederick Pfister; Berthold Schalke; Güher Saruhan-Direskeneli; Arthur Melms; Philipp Ströbel
Journal:  Autoimmun Rev       Date:  2013-03-25       Impact factor: 9.754

Review 7.  Unravelling the pathogenesis of myasthenia gravis.

Authors:  Angela Vincent
Journal:  Nat Rev Immunol       Date:  2002-10       Impact factor: 53.106

8.  Autoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity.

Authors:  Panos Stathopoulos; Anne Chastre; Patrick Waters; Sarosh Irani; Miriam L Fichtner; Erik S Benotti; Joel M Guthridge; Jennifer Seifert; Richard J Nowak; Jane H Buckner; V Michael Holers; Judith A James; David A Hafler; Kevin C O'Connor
Journal:  J Immunol       Date:  2019-03-01       Impact factor: 5.422

9.  Repertoire-wide phylogenetic models of B cell molecular evolution reveal evolutionary signatures of aging and vaccination.

Authors:  Kenneth B Hoehn; Jason A Vander Heiden; Julian Q Zhou; Gerton Lunter; Oliver G Pybus; Steven H Kleinstein
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-21       Impact factor: 11.205

10.  Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis.

Authors:  Miriam L Fichtner; Casey Vieni; Rachel L Redler; Ljuvica Kolich; Ruoyi Jiang; Kazushiro Takata; Panos Stathopoulos; Pablo A Suarez; Richard J Nowak; Steven J Burden; Damian C Ekiert; Kevin C O'Connor
Journal:  J Exp Med       Date:  2020-12-07       Impact factor: 14.307

View more
  2 in total

Review 1.  Novel pathophysiological insights in autoimmune myasthenia gravis.

Authors:  Gianvito Masi; Kevin C O'Connor
Journal:  Curr Opin Neurol       Date:  2022-08-04       Impact factor: 6.283

2.  Site-specific N-glycosylation characterization of micro monoclonal immunoglobulins based on EThcD-sceHCD-MS/MS.

Authors:  Mengqi Luo; Yonghong Mao; Wenjuan Zeng; Shanshan Zheng; Huixian Li; Juanjuan Hu; Xinfang Xie; Yong Zhang
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.